Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027960 (mole)
 21,279 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Expression of IGF-I mRNA and protein was evaluated in pigmented lesions by in situ hybridization and immunohistochemistry. An IGF-I cDNA clone (phigf1) was subcloned into pBluescript KS II-. Both sense and antisense 35S riboprobes were prepared and used for in situ hybridization on formalin-fixed, paraffin-embedded specimens. Control hybridizations with a beta-actin probe were also performed. Grains were counted in 787-microns2 melanocytic areas of sections hybridized with the antisense IGF-I probe. Seven common nevi contained a mean of 218 grains; nine dysplastic nevi, a mean of 463 grains; eight early primary melanomas, a mean of 402 grains; five advanced primary melanomas, a mean of 217 grains; and nine metastatic melanomas, a mean of 194 grains. The differences between common and dysplastic nevus, common nevus and early melanoma, early and advanced primary melanoma, and early primary melanoma and metastatic melanoma were statistically significant. Keratinocytes also expressed abundant IGF-I message. IGF-I protein was demonstrable by immunohistochemistry in melanocytes and keratinocytes. These results suggest that progression-associated variation occurs in the net expression of IGF-I mRNA in melanocytic tumors.
 ...
PMID:Expression of insulin-like growth factor I (IGF-I) in nevi and melanomas. 797 67

Ki-ras and c-myc oncogene mRNA in carcinoma tissue was quantitatively detected by the coamplification polymerase chain reaction. After the reverse transcription of the mRNA mixture with random hexanucleotide primer the coamplification polymerase chain reaction of the oncogene and the internal standard beta-actin cDNA was done. The amount of oncogene mRNA was calculated from the coamplified product ratio. Ki-ras expression in a human gastric cancer strain H-111 was estimated to 5 percent of beta-actin. The expression of c-myc mRNA in colorectal carcinoma tissue was observed to be ten to one hundred times higher than normal mucosa. Gene expression was compared numerically in mole/liter without using hybridization and radioactive probes.
 ...
PMID:Ki-ras and c-myc oncogene expression measured by coamplification polymerase chain reaction. 800 89

The level of parathyroid hormone-related protein (PTHrP) expressed in breast cancer tissue is closely related to the incidence of bone metastasis. We examined the PTHrP mRNA expression in breast cancer tissues by coamplification polymerase chain reaction (PCR) in mole ratio to internal standard beta-actin mRNA. The PTHrP expression was higher in premenopausal patients than in postmenopausal patients (P < 0.05). More pronounced difference by menopause found in estrogen receptor (ER) positive groups (P < 0.001) indicated that the PTHrP expression in breast cancer tissue is hormonally regulated and might be altered by endocrine agents. To clarify the changes of PTHrP expression by endocrine therapy of breast cancer, we measured PTHrP expression in the breast cancer tissue incubated for 24 h with 1 x 10(-8) M of estradiol (E2), 1 x 10(-6) M of tamoxifen (TAM) and 1 x 10(-5) M of medroxyprogesterone acetate (MPA). The PTHrP expression was decreased significantly by MPA (P < 0.005), while E2 and TAM did not change the PTHrP expression. Progesterone receptor (PgR) mRNA expression was also examined to confirm that the breast cancer tissue responds to E2 and TAM. The results were well compatible with the better therapeutic effect of MPA reported for the treatment of breast cancer with bone metastases. As a potential candidate for the receptor that mediates the suppressive effect of MPA, androgen receptor (AR) is suggested most probable. Present results also demonstrated that the clinical response of individual tumors is closely associated with the early in vitro changes of gene expression detected in the cancer specimen.
 ...
PMID:Suppression of parathyroid hormone-related protein messenger RNA expression by medroxyprogesterone acetate in breast cancer tissues. 1051 39